Successful management of claustrophobia and depression during allogeneic SCT

Eur J Haematol. 2001 Jul;67(1):54-5. doi: 10.1034/j.1600-0609.2001.067001054.x.

Abstract

As psychological problems are frequent in SCT patients we report on a patient with chronic myeloid leukemia, claustrophobia and depression. The successful allogeneic stem cell transplant of this patient in a reverse isolation setting required intensive interdisciplinary hematological, psychological and psychiatric collaboration. Psychopharmacologically the patient was treated with lorazepam 1 mg at 10 a.m. and 8 p.m. and after crisis on day +6, and 2.5 mg twice daily i.v. until one day before discharge (total 20 doses). Psychological counseling followed a cognitive-behavioural approach including progressive muscle relaxation and cognitive techniques focusing on the actual coping processes.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Anti-Anxiety Agents / therapeutic use*
  • Anxiety / drug therapy
  • Anxiety / etiology
  • Cognitive Behavioral Therapy*
  • Combined Modality Therapy
  • Craniotomy
  • Depressive Disorder, Major / drug therapy
  • Depressive Disorder, Major / etiology
  • Depressive Disorder, Major / therapy*
  • Drainage
  • Habituation, Psychophysiologic
  • Headache / etiology
  • Hematopoietic Stem Cell Transplantation / adverse effects
  • Hematopoietic Stem Cell Transplantation / psychology*
  • Humans
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / psychology
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
  • Lorazepam / therapeutic use*
  • Lymphangioma, Cystic / etiology
  • Lymphangioma, Cystic / surgery
  • Male
  • Panic Disorder / drug therapy
  • Panic Disorder / etiology
  • Panic Disorder / therapy
  • Patient Isolation / psychology*
  • Phobic Disorders / drug therapy
  • Phobic Disorders / etiology
  • Phobic Disorders / therapy*
  • Relaxation Therapy*

Substances

  • Anti-Anxiety Agents
  • Lorazepam